Advanced Therapy Medicinal Products Market Report 2026

Advanced Therapy Medicinal Products Market Overview

• Advanced Therapy Medicinal Products market size has reached to $51.34 billion in 2025 • Expected to grow to $124.43 billion in 2030 at a compound annual growth rate (CAGR) of 19.3% • Growth Driver: Rise In Personalized Medicine Tailoring Treatment Approaches For Chronic And Rare Diseases • Market Trend: Advancements In Gene-Editing Cell Therapies Drive Precision Treatment In Genetic Blood Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Advanced Therapy Medicinal Products Market?

Advanced therapy medicinal products are medicines based on genes, cells, or tissue engineering that offer innovative treatments for a wide range of diseases and injuries. These therapies work by repairing, replacing, or regenerating human cells, tissues, or organs to restore normal function. The main product types of advanced therapy medicinal products are somatic cell therapy medicinal products, tissue-engineered medicinal products, and gene therapy medicinal products. Somatic cell therapy medicinal products refer to treatments that use cells from the human body (excluding reproductive cells) that are manipulated or processed to treat, prevent, or cure diseases by repairing or replacing damaged tissues or cells. These therapies utilize a range of technologies such as gene editing technologies, viral vector technology, stem cell technology, and automation and artificial intelligence-driven processes. They are applied in the treatment of various conditions, including muscular dystrophies, Alzheimer’s, hemophilia, cystic fibrosis, and other applications. Distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy. serving a broad range of end users such as hospitals, specialty clinics, and other end users

What Is The Advanced Therapy Medicinal Products Market Growth Forecast?

The advanced therapy medicinal products market size is expected to see rapid growth in the next few years. It will grow to $124.43 billion in 2030 at a compound annual growth rate (CAGR) of 19.3%. The growth in the forecast period can be attributed to technological advancements in gene editing and stem cell therapies, rising investment in personalized medicine, increasing prevalence of rare and chronic diseases, expansion of hospital pharmacy and specialty clinic networks, integration of ai-driven manufacturing and automation processes. Major trends in the forecast period include rising adoption of autologous and allogeneic therapies, expansion of gene editing and viral vector technologies, increasing focus on rare disease treatments, integration of automation in therapy manufacturing, growing hospital and specialty clinic collaborations.

Global Advanced Therapy Medicinal Products Market Segmentation

1) By Product: Somatic Cell Therapy Medicinal Products, Tissue Engineered Medicinal Products, Gene Therapy Medicinal Products 2) By Technology: Gene Editing Technologies, Viral Vector Technology, Stem Cell Technology, Automation And Artificial Intelligence-Driven Processes 3) By Application: Muscular Dystrophies, Alzheimer’s, Hemophilia, Cystic Fibrosis, Other Applications 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy 5) By End User: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Somatic Cell Therapy Medicinal Products: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, Dendritic Cell Therapy, Natural Killer Cell Therapy 2) By Tissue Engineered Medicinal Products: Autologous Tissue-Engineered Products, Allogeneic Tissue-Engineered Products, Scaffold-Based Tissue Engineering, Scaffold-Free Tissue Engineering, Skin Substitutes 3) By Gene Therapy Medicinal Products: In Vivo Gene Therapy, Ex Vivo Gene Therapy, Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Gene Editing Therapies

What Is The Driver Of The Advanced Therapy Medicinal Products Market?

The rising demand for personalized medicine is expected to propel the growth of the advanced therapy medicinal products market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The rising demand for personalized medicine is primarily due to the increasing prevalence of chronic diseases, as it enables tailored treatments that improve outcomes and reduce side effects for individual patients. Advanced therapy medicinal products enable personalized medicine by offering tailored treatments such as gene, cell, and tissue-engineered therapies that target the unique genetic and biological profiles of individual patients. for instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine drives the growth of the advanced therapy medicinal products industry.

Key Players In The Global Advanced Therapy Medicinal Products Market

Major companies operating in the advanced therapy medicinal products market are F. Hoffmann-La Roche Limited., Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited., Lonza Group AG, Catalent Inc., BioMarin Pharmaceutical Inc., AGC Biologics Inc., ViaCyte Inc., Rentschler Biopharma SE, JCR Pharmaceuticals Co. Ltd., Vericel Corporation, UniQure N.V., Fate Therapeutics Inc., WuXi Advanced Therapies Inc., Celonic Group AG, Pharmicell Co. Ltd., Magenta Therapeutics Inc, MEDIPOST Co. Ltd., Kolon TissueGene Inc

Global Advanced Therapy Medicinal Products Market Trends and Insights

Major companies operating in the advanced therapy medicinal products (ATMP) market are focusing on developing innovative treatments, such as gene editing cell therapies, to offer targeted and potentially curative treatments for conditions like β thalassemia and sickle cell disease. Gene editing cell therapies involve collecting a patient’s hematopoietic stem cells and precisely modifying their genome ex vivo, often using CRISPR Cas9 to correct harmful mutations or activate beneficial genetic pathways, providing a personalized alternative to traditional allogeneic bone marrow transplantation, which relies on donor matching and carries risks such as graft versus host disease. For instance, in January 2024, Vertex Pharmaceuticals, a US based biotechnology company, received US Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel, or exa cel), a CRISPR Cas9 based gene editing cell therapy for transfusion dependent β thalassemia. The therapy uses autologous CD34+ stem and progenitor cells, edits the erythroid specific BCL11A enhancer to elevate fetal hemoglobin levels, and has demonstrated sustained clinical improvements, with the potential to achieve transfusion independence for many patients and significantly reduce or eliminate the need for regular blood transfusions.

What Are Latest Mergers And Acquisitions In The Advanced Therapy Medicinal Products Market?

In May 2024, Tri-Tech Forensics Inc., a US-based forensic company, acquired SAM Medical Products for an undisclosed amount. The acquisition is expected to help Tri-Tech Forensics expand its emergency medical product portfolio and strengthen its position in the market. SAM Medical Products is a US-based company that develops, manufactures and markets orthopedic splints, and wound care devices, medical services products designed for various professionals in the medical field.

Regional Insights

North America was the largest region in the advanced therapy medicinal products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Advanced Therapy Medicinal Products Market?

The advanced therapy medicinal products market consists of revenues earned by entities by providing services such as cell and gene therapy development services, viral vector production and characterization, regulatory and clinical trial support, analytical testing and quality control services, and process development and scale-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced therapy medicinal products market also includes sales of gene therapy vectors, engineered tissue scaffolds, bioengineered skin substitutes, and encapsulated cell therapies. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Advanced Therapy Medicinal Products Market Report 2026?

The advanced therapy medicinal products market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the advanced therapy medicinal products industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.